letrozole / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 114 Diseases   361 Trials   361 Trials   7200 News 


«12345678910111213...100101»
  • ||||||||||  goserelin acetate / Generic mfg., letrozole / Generic mfg.
    Journal, Heterogeneity:  A weighted Bayesian integration method for predicting drug combination using heterogeneous data. (Pubmed Central) -  Sep 29, 2024   
    This new method enhances the performance of drug combination predictions, enabling effective pre-screening for trials and, thereby, benefiting clinical treatments. Future research should focus on developing new methods for application in various scenarios and for integrating diverse data sources.
  • ||||||||||  5-fluorouracil / Generic mfg.
    SUCCESSFUL MANAGEMENT OF A CASE OF HEREDITARY ANGIOEDEMA TRIGGERED BY CHEMOTHERAPY (Monitor 6; Hall A) -  Sep 29, 2024 - Abstract #ACAAI2024ACAAI_664;    
    Case Description: We present a case of a 49 year-old woman with HAE with reduced C1 inhibitor and recently diagnosed diffuse large B cell lymphoma who presented to Allergy Clinic for management of HAE after initiation of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...Lanadelumab and pd-C1INH combination represents a potential option for prophylaxis of HAE during chemotherapy. Our case also highlights that icatibant should not be used for HAE prophylaxis.
  • ||||||||||  letrozole / Generic mfg.
    Preclinical, Journal:  The Effects of L-Tartaric Acid on Ovarian Histostereological and Serum Hormonal Analysis in an Animal Model of Polycystic Ovary Syndrome. (Pubmed Central) -  Sep 28, 2024   
    Forty adult Sprague Dawley rats were randomly divided into four groups including controls (no intervention), Tartaric acid (40mg/Kg/day from day 21 onwards for 39 days), PCOS (21 days letrozole and then normal saline orally for 39 days), and PCOS?+?Tartaric acid...Furthermore, tartaric acid improved the serum levels of LH, estradiol, progesterone, and testosterone (p-value?<?0.05). The obtained findings may suggest tartaric acid as a novel strategy for PCOS management, although further studies are necessary.
  • ||||||||||  Piqray (alpelisib) / Novartis, Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
    Gastric Metastasis from Breast Cancer Detected on 18F-FDG PET-CT A Rare Finding (e-Poster Area) -  Sep 27, 2024 - Abstract #EANM2024EANM_2580;    
    This can lead to misdiagnosis of metastatic disease and insufficient treatment of the patient, which can later lead to disease progression or recurrence. Therefore, any abnormal metabolically active thickening in the stomach must be evaluated thoroughly even though it might appear innocuous.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  Polysaccharide-fecal microbiota-based colon-targeted self-nanoemulsifying drug delivery system of curcumin for treating polycystic ovarian syndrome. (Pubmed Central) -  Sep 24, 2024   
    Pharmacokinetic and pharmacodynamic evaluation was carried out on letrozole-induced female Wistar rats...The pharmacodynamic study indicated excellent recovery/reversal in the rats treated with CCM-CT-S-SNEDDS low and high dose containing FME (group 13 and group 14) in a dose-dependent manner. The developed formulation showcasing its improved bioavailability, targeted action, and therapeutic activity in ameliorating PCOS can be utilized as an adjuvant therapy for developing a dosage form, scale-up, and technology transfer.
  • ||||||||||  letrozole / Generic mfg.
    Trial completion date, Trial primary completion date:  Myo-Inositol for Infertility in PCOS (clinicaltrials.gov) -  Sep 21, 2024   
    P=N/A,  N=168, Recruiting, 
    The developed formulation showcasing its improved bioavailability, targeted action, and therapeutic activity in ameliorating PCOS can be utilized as an adjuvant therapy for developing a dosage form, scale-up, and technology transfer. Trial completion date: Aug 2024 --> Dec 2025 | Trial primary completion date: Aug 2024 --> Jun 2025
  • ||||||||||  Kadcyla (ado-trastuzumab emtansine) / Roche
    Journal:  Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study. (Pubmed Central) -  Sep 20, 2024   
    A 54-year-old postmenopausal female patient with recurrent breast cancer and metastasis was treated with trastuzumab and paclitaxel (12 cycles), followed by trastuzumab maintenance therapy (71 cycles)...Oral therapy with lapatinib and letrozole was prescribed for a year to treat the breast cancer, along with the lesions and enhanced nodules observed in the patient's lungs, liver, and bones...This case report demonstrates the long-term efficacy of T-DM1 and its satisfactory safety profile. Overall, it provides valuable insights into the management of and challenges faced during the treatment of recurrent breast cancer with metastasis.
  • ||||||||||  letrozole / Generic mfg., tamoxifen / Generic mfg., everolimus / Generic mfg.
    Trial completion, Trial completion date, Metastases:  Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer (clinicaltrials.gov) -  Sep 20, 2024   
    P2,  N=74, Completed, 
    Trial completion date: Jul 2024 --> Jan 2025 Active, not recruiting --> Completed
  • ||||||||||  Journal, Adverse events:  Risk of ocular adverse events with aromatase inhibitors. (Pubmed Central) -  Sep 19, 2024   
    Disproportionality analysis revealed an increased risk of ocular AEs with each of the AIs. This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities.
  • ||||||||||  HRS-8080 / Jiangsu Hengrui Pharma, HRS-6209 / Jiangsu Hengrui Pharma, HRS-1358 / Jiangsu Hengrui Pharma
    Enrollment open, Combination therapy, Metastases:  A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=528, Recruiting, 
    This study calls for clinicians, especially oncologists and ophthalmologists, to be vigilant in patients who are on AI therapy, allowing them to provide prompt interventions to mitigate further ocular morbidities. Not yet recruiting --> Recruiting
  • ||||||||||  bireociclib (XZP 3287) / Sihuan Pharmaceutical
    Enrollment closed, Enrollment change, Trial completion date:  A Phase I/II Study of XZP-3287 in Metastasis Solid Tumors (clinicaltrials.gov) -  Sep 19, 2024   
    P1/2,  N=402, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=300 --> 402 | Trial completion date: Dec 2022 --> Dec 2025
  • ||||||||||  Ameile (aumolertinib) / Jiangsu Hansoh Pharma
    Multiple primary cancers (MPC) of breast and lung with primary EGFR T790M mutation Responded to Aumolertinib: A case report (Hall 407) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1306;    
    For lung adenocarcinoma, she commenced treatment with pemetrexed plus carboplatin for 1 cycle, starting in October 2022, in conjunction with fluvestrant...For Breast cancer (cT2N1Mx Luminal B), considering the enlargement of the breast tumor that letrozole therapy previously, she received endocrine therapy with fluvestrant 500mg once every 28 days... This report presents the first case of applying aumolertinib for primary EGFR T790M mutations in patients with MPC of breast and lung, offering a promising treatment approach for the future survival of such patients.
  • ||||||||||  BRAF mutation in HR positive HER2 negative advanced breast cancer (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1090;    
    She received second line Abemaciclib and Fulvestrant but progressed rapidly after 3 months...Clinical resistance to Dabrafenib and Trametinib was most likely associated with acquisition of the TYW1-BRAF and RABEP1-BRAF fusion genes...We report a rare case of breast cancer with BRAF mutation in which genomic profiling was used to direct therapy and the excellent response to treatment. Serial molecular profiling identified a novel BRAF fusion as the likely acquired resistance to BRAF inhibitors.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Breast Carcinoma disguised as Systemic Sclerosis: A case report of unusual Paraneoplastic Syndrome (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_1088;    
    However, the disease progressed, and treatment was shifted to mycophenolate mofetil and Nintedanib...The first line of treatment with ribociclib and letrozole was initiated...The lack of response to conventional systemic sclerosis therapy but improvement with the underlying malignancy treatment suggests the case's possible paraneoplastic origin. This case report may further improve awareness of the natural course of the disease, preventing a potential cancer treatment delay.
  • ||||||||||  Kisqali (ribociclib) / Novartis
    Ethnicity assessment of ribociclib pharmacokinetics in advanced breast cancer patients (Exhibition area) -  Sep 17, 2024 - Abstract #ESMOAsia2024ESMO_Asia_413;    
    In addition, at 400 mg dose, PK exposure (AUC, C max and/or C trough ) in Japanese patients was comparable to non-Japanese Asian patients (A2115) and global patients (the sample size in A2115 was small). Conclusions Considering ribociclib PK variability and inter-study variabilities, PK exposure of ribociclib were largely comparable between Caucasian and Asian patients with aBC.
  • ||||||||||  letrozole / Generic mfg.
    Journal:  True empty follicle syndrome is a subtype of oocyte maturation abnormalities. (Pubmed Central) -  Sep 4, 2024   
    The treatment approaches included letrozole-primed IVM, follicle-stimulating hormone (FSH)-human chorionic gonadotrophin (hCG)-primed IVM, and conventional IVF...These conditions are observed in OMAs due to defects in the oocyte machinery. The proposed flowchart provides a comprehensive classification approach for various forms of EFS.
  • ||||||||||  LOXO-783 / Eli Lilly
    Enrollment closed, Enrollment change, Combination therapy, Monotherapy, Metastases:  PIKASSO-01: A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors (clinicaltrials.gov) -  Sep 4, 2024   
    P1,  N=193, Active, not recruiting, 
    The proposed flowchart provides a comprehensive classification approach for various forms of EFS. Recruiting --> Active, not recruiting | N=400 --> 193
  • ||||||||||  Irene (pyrotinib) / Jiangsu Hengrui Pharma, Focus V (anlotinib) / Advenchen, Sino Biopharm
    Journal:  Case report: outcome of anlotinib treatment in breast cancer patient with brain metastases. (Pubmed Central) -  Sep 3, 2024   
    After the standard first-line treatment including albumin-bound paclitaxel, trastuzumab and pertuzumab, and a second-line treatment involving pyrotinib, capecitabine, and radiotherapy did not produce the desired results, the patient was then administered anlotinib in combination with pyrotinib and letrozole as a third-line treatment, which led to a partial response (PR). The findings suggest that anti-angiogenic therapy, specifically anlotinib, could be regarded as a promising therapeutic option for BC patients with BM.
  • ||||||||||  letrozole / Generic mfg., anastrozole / Generic mfg., exemestane / Generic mfg.
    Journal, Adverse events:  Adverse Event Profiles of the Third-Generation Aromatase Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS. (Pubmed Central) -  Aug 31, 2024   
    Additionally, letrozole was also associated with lots of other rare but serious AEs in hematologic, respiratory, and hepatic systems, which were not recorded in the instructions. Our analysis of safety warning signals of the third-generation AIs from the FAERS database provided reference for clinical safe and rational drug use.
  • ||||||||||  Mekinist (trametinib) / Novartis, BeiGene, Tafinlar (dabrafenib) / Novartis, Imbruvica (ibrutinib) / AbbVie, J&J
    Dual Oncologic Challenges: Managing Chronic Lymphocytic Leukemia With Concurrent Melanoma and Breast Cancer: A Case Report (LEVEL 3, HALL B3) -  Aug 30, 2024 - Abstract #SOHO2024SOHO_504;    
    This case underscores the complex interplay between hematologic malignancies and solid tumors, highlighting the increased susceptibility to second primary malignancies in patients with CLL. It emphasizes the challenges of diagnostic workup and management of these patients, the need for interdisciplinary approaches, and the need for further research into preventive and treatment strategies for these intricate oncology cases.
  • ||||||||||  Ibrance (palbociclib) / Pfizer
    Trial completion, HEOR, Combination therapy, Real-world evidence, Real-world, Metastases:  Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy (clinicaltrials.gov) -  Aug 23, 2024   
    P=N/A,  N=813, Completed, 
    As certain eligible groups had a prognosis similar to non-eligible patients, it might be interesting to explore additional patient groups for CDK4/6i therapy. Active, not recruiting --> Completed